VDO test

TISTOK SAA //--> 02 min 58 sec TISTOK SAA EP1. Diagnosis and Treatment

Assist.Prof. Sira Nanthapisal

Criteria of Ribociclib reimbursement in SSS Download × //-->Show More

Redefining the ASCVD management through Effective & Sustained LDL-C reduction with siRNA //--> 9 min 9 sec LDL-C is the Primary Target for ASCVD: Treat Early, Treat-to-Target, Treat Lifelong

ASSOC. PROF. PATTARAPONG MAKARAWATE, MD Cardiologist, Khon Kaen University Hospital

//--> 14 min 32 sec CASE SHARING: Young Hearts, Multi-Vessel Disease

Stay committed to your goal: Unleashing the Future of Lipid Management //--> 01 hr 00 min 14 sec Stay committed to your goal: Unleashing the Future of Lipid Management

Prof. Thananya Boonyasirinant, M.D. Siriraj Hospital

Assoc. Prof. Arintaya Phrommintikul, M.D. Chiang Mai University Hospital

Dr. Prin Vathesatogkit, M.D. Ramathibodi Hospital

10 mins : Everolimus in reducing rejection rates //--> 10 min 24 sec Snapshot: Decision chart in the most prevalent phenotypes of severe asthma

Prof.Dr.Kittipong M.

Home Show More

Snapshot: Decision chart in the most prevalent phenotypes of severe asthma //--> 1 min 20 sec Snapshot: Decision chart in the most prevalent phenotypes of severe asthma

Prof.Dr.Kittipong M.

Home Show More

Ask Speakers

TISTOK SAA

Breast Cancer Publication

Thailand Lipid Expert Connect 2025

CMCC: Novartis Lunch symposium (2024)

Efficacy of Everolimus in reducing rejection

Snapshot: Decision chart in the most prevalent phenotypes of severe asthma

Medical Information Request